Evaluating heart failure with preserved ejection fraction using advanced imaging techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates heart failure with preserved ejection fraction (HFpEF) by utilizing multimodality imaging techniques, including cardiovascular magnetic resonance imaging, echocardiography, and nuclear medicine imaging. It aims to identify cardiac features, early diagnosis, and risk factors associated with HFpEF in a multicenter population. The study combines large data analysis and artificial intelligence to enhance understanding of this condition, which is often underdiagnosed and misunderstood. By focusing on early identification and intervention, the research seeks to improve patient outcomes and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* left ventricular ejection fraction (LVEF)≥50%；
* N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml;
* symptoms and syndromes of heart failure;
* At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).

Exclusion Criteria:

* Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
* Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
* Severe arrhythmia;
* Severe primary cardiac valvular disease;
* Restrictive pericardial disease;
* Refuse to participate in the study.

Where it's running

• Fuwai Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Minjie Lu, PhD
• Email: coolkan@163.com
• Phone: 86 10 88396941

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can a multi-omics and AI model predict ABPA relapse within 1 year in adults?

  This study tests a machine learning model that uses multi-omics and clinical data to predict the 1-year relapse risk for adults with ABPA who are in a stable state.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07611838

• Incretin therapy with tirzepatide for obesity-related HFpEF

  A 15-month study will test whether tirzepatide helps people with obesity and HFpEF by reducing plasma volume.

  Recruiting Phase 4 Columbia University · New York, New York · NCT07554638

• LY3971297 in heart failure: safety and tolerability in HF with preserved and reduced ejection fraction

  This study tests how well LY3971297 is tolerated and what side effects occur in people with HFpEF or HFrEF.

  Recruiting Phase 1 Eli Lilly and Company · Detroit, Michigan and 11 other locations · NCT07547540

• Acetazolamide versus metolazone added to usual diuretics for acute decompensated heart failure

  This trial will test whether adding acetazolamide or metolazone to standard diuretics works better and is safer for adults hospitalized with acute decompensated heart failure.

  Recruiting University of Health Sciences Lahore · Chak Eighty-seven -Twelve Left, Punjab Province · NCT07199088

• Tracking suicide attempts and suicidal thoughts in Flanders

  This project collects detailed information about people in Flanders who have suicidal thoughts or who have survived suicide attempts to see how often these events happen, which methods are used, and whether they get follow-up care.

  Recruiting at 32 sites University Hospital, Ghent · Aalst and 32 other locations · NCT07021404

• Effect of BCG and Tislelizumab on Bladder Cancer

  This study is testing if combining a vaccine called BCG with a new drug called tislelizumab can help people with intermediate and high-risk bladder cancer have fewer recurrences after surgery.

  Recruiting Phase 3 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06441110

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.